NFE2L2 and neoplasm: Moving into predictive insights, KEAP1 and NFE2L2-mutant tumors exhibit reduced responsiveness to immune-checkpoint inhibitors (ICIs), likely due to an immunosuppressive microenvironment, characterized by low tumor mutational burden, reduced interferon signaling, and decreased CD8+ T cell infiltration.